Eckerd v. Merck suit
Firms settle antitrust suit filed by Jack Eckerd in Tampa Federal Court against Merck, challenging the manufacturer's single-price whslr./retailer policy. "The detailed provisions of the settlement are subject to a confidentiality agreement," the firms said in a joint Aug. 7 press release. The settlement does "not alter the prices and terms of sale by Merck to Eckerd, which are in accordance with Merck's publicly announced price lists." At the time of the suit's filing in 1982, the chain claimed that it would lose $900,000 in gross profits that fiscal year resulting from Merck's elimination of the 5% whslr. discount ("The Pink Sheet" April 12, 1982, p. 5).
You may also be interested in...
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.